Related Experiment Video

Updated: May 8, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Update on hepatocellular carcinoma breakthroughs: poly(ADP-ribose) polymerase inhibitors as a promising therapeutic

Clément Guillot1, Janet Hall2, Zdenko Herceg3

  • 1UMR INSERM U1052 CNRS5286, CRCL, 151, cours Albert-Thomas, 69008 Lyon, France; Université Lyon-1, 69622 Villeurbanne, France; International Agency for Research on Cancer, 150, cours Albert-Thomas, 69424 Lyon cedex 03, France.

Clinics and Research in Hepatology and Gastroenterology
|August 20, 2013
PubMed

Insights

Poly(ADP-ribose) polymerase (PARP) inhibitors show promise for treating hepatocellular carcinoma, a common liver cancer. These drugs may enhance radiation sensitivity and improve patient outcomes when used alone or with other therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Radiotherapy

Background:

  • Hepatocellular carcinoma (HCC) is a leading cause of cancer death globally.
  • Curative treatment options for HCC are limited, affecting only 10-20% of patients.
  • Novel therapeutic strategies are urgently needed to improve outcomes for the majority of HCC patients.

Purpose of the Study:

  • To review the role of Poly(ADP-ribose) polymerase-1 (PARP-1) in hepatocellular carcinoma.
  • To assess the potential of PARP inhibition as a therapeutic strategy for HCC.
  • To explore the efficacy of PARP inhibitors as single agents or in combination with chemotherapy or radiotherapy.

Main Methods:

  • Review of preclinical studies on PARP inhibition in HCC models.
  • Analysis of the role of PARP-1 in DNA repair and its implications for cancer therapy.
  • Evaluation of data from phase 1/2 trials on conformal radiotherapy for HCC.

Main Results:

  • Preliminary data suggest conformal radiotherapy has promising curative effects in HCC.
  • Poly(ADP-ribose) polymerase (PARP) inhibitors demonstrate radio- and chemo-sensitizing properties.
  • PARP inhibition shows potential as a single agent or in combination therapies for HCC.

Conclusions:

  • PARP-1 plays a significant role in hepatocellular carcinoma.
  • PARP inhibition represents a promising therapeutic avenue for HCC, potentially enhancing the effectiveness of radiotherapy and chemotherapy.
  • Further investigation into PARP inhibitors could lead to improved clinical outcomes for HCC patients.

More Related Videos

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...